The use of methylphenidate hydrochloride extended-release oral suspension for the treatment of ADHD

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Expert Review of Neurotherapeutics

• Publication date

  2013-09-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1586/14737175.2013.833002PMID 24053342
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Characterization of adolescent prescription drug abuse and misuse using the Researched Abuse Diversion and Addiction-related Surveillance (RADARS(®)) System.

  2013cited by this paper
• NWP06, an Extended-Release Oral Suspension of Methylphenidate, Improved Attention-Deficit/Hyperactivity Disorder Symptoms Compared with Placebo in a Laboratory Classroom Study

  2013cited by this paper
• A pilot open label prospective study of memantine monotherapy in adults with ADHD

  2013cited by this paper
• ADHD: Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents

  2012cited by this paper
• Do prescription stimulants increase the risk of adverse cardiovascular events?: A systematic review

  2012cited by this paper
• Clinical and functional outcome of childhood attention-deficit/hyperactivity disorder 33 years later.

  2012cited by this paper
• Time Course of Treatment Effect of OROS® Methylphenidate in Children With ADHD

  2012cited by this paper
• A systematic review and analysis of long-term outcomes in attention deficit hyperactivity disorder: effects of treatment and non-treatment

  2012cited by this paper
• Medication for attention deficit-hyperactivity disorder and criminality.

  2012cited by this paper
• Economic impact of childhood and adult attention-deficit/hyperactivity disorder in the United States.

  2012cited by this paper
• Neurobiological circuits regulating attention, cognitive control, motivation, and emotion: disruptions in neurodevelopmental psychiatric disorders.

  2012cited by this paper
• Single-Dose Pharmacokinetics of NWP06, an Extended-Release Methylphenidate Suspension, in Children and Adolescents with ADHD

  2011cited by this paper
• ADHD: Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents

  2011cited by this paper
• The Single-Dose Pharmacokinetics of NWP06, a Novel Extended-Release Methylphenidate Oral Suspension

  2010cited by this paper
• Structure and diagnosis of adult attention-deficit/hyperactivity disorder: analysis of expanded symptom criteria from the Adult ADHD Clinical Diagnostic Scale.

  2010cited by this paper
• Increasing prevalence of parent-reported attention-deficit/hyperactivity disorder among children --- United States, 2003 and 2007.

  2010cited by this paper
• Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR)

  2010cited by this paper
• Ion-exchange resins as drug delivery carriers.

  2009cited by this paper
• Parental Report of Medication Acceptance Among Youth: Implications for Everyday Practice

  2008cited by this paper
• Onset of Efficacy of Long-Acting Psychostimulants in Pediatric Attention-Deficit/Hyperactivity Disorder

  2008cited by this paper
• Varying the wear time of the methylphenidate transdermal system in children with attention-deficit/hyperactivity disorder.

  2008cited by this paper
• Cognitive and Behavioral Effects of Multilayer-Release Methylphenidate in the Treatment of Children with Attention-Deficit/Hyperactivity Disorder

  2008cited by this paper
• Do Formulation Differences Alter Abuse Liability of Methylphenidate?: A Placebo-Controlled, Randomized, Double-Blind, Crossover Study in Recreational Drug Users

  2007cited by this paper
• Adolescents’ struggles with swallowing tablets: barriers, strategies and learning

  2007cited by this paper
• Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder.

  2007cited by this paper
• The worldwide prevalence of ADHD: a systematic review and metaregression analysis.

  2007cited by this paper
• A Pilot Evaluation of the Safety, Tolerability, Pharmacokinetics, and Effectiveness of Memantine in Pediatric Patients with Attention-Deficit/Hyperactivity Disorder Combined Type

  2007cited by this paper
• Pill Swallowing Ability and Training in Children 6 to 11 Years of Age

  2006cited by this paper
• A randomized, controlled effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release methylphenidate in attention deficit-hyperactivity disorder.

  2006cited by this paper
• A Randomized, Double-Blind, Placebo-Controlled, Laboratory Classroom Assessment of Methylphenidate Transdermal System in Children With ADHD

  2006cited by this paper
• Emotional and Behavioral Difficulties and Impairments in Everyday Functioning Among Children With a History of Attention-Deficit/Hyperactivity Disorder

  2006cited by this paper
• The American Psychiatric Association

  2005cited by this paper
• Patterns and predictors of attention-deficit/hyperactivity disorder persistence into adulthood: results from the national comorbidity survey replication.

  2005cited by this paper
• A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study).

  2004cited by this paper
• Mechanism of action of methylphenidate: Insights from PET imaging studies

  2002cited by this paper
• Reliability and validity of the SKAMP rating scale in a laboratory school setting.

  1998cited by this paper
• Sustained release and standard methylphenidate effects on cognitive and social behavior in children with attention deficit disorder.

  1987cited by this paper
• BEHAVIOR OF CHILDREN RECEIVING BENZEDRINE

  1938cited by this paper

• Overview of approved psychiatric medications 2008-2023: A systematic review

  2024cites this paper
• Pediatric Drug Delivery Challenges: Enhancing Compliance Through Age-appropriate Formulations and Safety Measures

  2024cites this paper
• Stimulants.

  2022cites this paper
• Advancements in Formulation Approaches to Pediatric Oral Drug Delivery systems

  2021cites this paper
• Neonatal and pediatric oral drug delivery: Hopes and hurdles.

  2021cites this paper
• Recent updates in the Alzheimer's disease etiopathology and possible treatment approaches: a narrative review of current clinical trials.

  2020cites this paper
• Distinct long non-coding RNA and mRNA expression profiles in the hippocampus of an attention deficit hyperactivity disorder model in spontaneously hypertensive rats and control wistar Kyoto rats.

  2020cites this paper
• New Formulations of Stimulants: An Update for Clinicians

  2019cites this paper
• Enhancing the understanding of palatability assessment used in the development of paediatric medicines

  2019cites this paper
• Progress in agonist therapy for substance use disorders: Lessons learned from methadone and buprenorphine.

  2019cites this paper
• A Study of an ADHD Experience Video Game's Effect on Users' Attention

  2019cites this paper
• Ethanol Interactions With Dexmethylphenidate and dl-Methylphenidate Spheroidal Oral Drug Absorption Systems in Healthy Volunteers

  2017cites this paper
• Efficacy and Safety of a Chewable Methylphenidate Extended-Release Tablet in Children with Attention-Deficit/Hyperactivity Disorder

  2017cites this paper
• Methylphenidate extended-release oral suspension for the treatment of attention-deficit/hyperactivity disorder: a practical guide for pharmacists

  2017cites this paper
• The Revised Korean Practice Parameter for the Treatment of Attention-Deficit Hyperactivity Disorder ( IV )-Non-Pharmacologic Treatment

  2017cites this paper
• The Revised Korean Practice Parameter for the Treatment of Attention-Deficit Hyperactivity Disorder (IV) - Non-Pharmacologic Treatment -

  2017cites this paper
• New Formulations of Methylphenidate for the Treatment of Attention-Deficit/Hyperactivity Disorder: Pharmacokinetics, Efficacy, and Tolerability

  2017cites this paper
• From Clinical Application to Cognitive Enhancement: The Example of Methylphenidate

  2016cites this paper
• The Guideline of Diagnosis and Treatment of Attention-Deficit Hyperactivity Disorder: Developed by ADHD Translational Research Center

  2016cites this paper
• Single-dose Pharmacokinetic Properties and Relative Bioavailability of a Novel Methylphenidate Extended-release Chewable Tablet Compared With Immediate-release Methylphenidate Chewable Tablet.

  2016cites this paper
• Expert Opinion and Recommendations for the Management of Attention-Deficit/Hyperactivity Disorder in Correctional Facilities

  2016cites this paper
• Should we continue methylphenidate treatment despite orofacial or extremity dyskinesias

  2015cites this paper
• Medications used in the treatment of disruptive behavior in children with FASD--a guide.

  2015cites this paper
• Formulation approaches to pediatric oral drug delivery: benefits and limitations of current platforms

  2015cites this paper
• Psychostimulant addiction treatment.

  2014cites this paper
• Attention Deficit Hyperactivity Disorder in Children

  2014cites this paper
• Long-acting methylphenidate formulations in the treatment of attention-deficit/hyperactivity disorder: a systematic review of head-to-head studies

  2013cites this paper